Global Gene Therapy Partnering Terms and Agreements Report 2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development – QNT Press Release

DUBLIN, Sept. 9, 2022 /PRNewswire/ — The “Global Gene Therapy Partnering Terms and Agreements 2010 to 2022” report has been added to’s offering.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 650 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties.

  • Trends in gene therapy partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene therapy partnering contract documents
  • Top gene therapy deals by value

The Global Gene Therapy Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Gene Therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene Therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.


Full story available on

Source link

Recommended For You

About the Author: News Center